Announcements Trials

Browse Landscape

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Specimen Handling 125 pembrolizumab 123 Magnetic Resonance Spectroscopy 108 Carboplatin 89 Cyclophosphamide 80 Biopsy 69 Cisplatin 67 Paclitaxel 61 Bevacizumab 56 Gemcitabine 54 Nivolumab 49 fludarabine 48 Dexamethasone 41 Rituximab 39 Pemetrexed 39 Fluorouracil 39 Radiotherapy 37 Doxorubicin 37 atezolizumab 36 Docetaxel 36 Leucovorin 35 Oxaliplatin 32 Capecitabine 32 venetoclax 31 Temozolomide 29 Prednisone 29 durvalumab 27 Standard of Care 27 Radiation 27 Letrozole 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Sulfonylurea Compounds × 30 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡